



JULY 1-2, 2021

# Course on Molecular Pathology and Targeted Therapy in Gynaecological Cancers

ONLINE COURSE

## Scientific Programme – Online Course

Chairs: Ledermann, Matias-Guiu, Creutzberg, Fagotti

Day 1 – July 1, 2021			
08:30	<b>Introduction Welcome – Purpose of the course</b>	Chairs: <i>Ledermann, Matias-Guiu</i>	
	<b>Session 1: Molecular Markers in High Grade Ovarian Cancer</b>	Chair: Ledermann	
8:40	P53 mutations, Precursor lesions mutations and immunological markers- what do they signify?	<i>McCluggage</i>	0:20
9:00	BRCA mutations – Pathological and Variants of unknown significance and other genes associated with hereditary ovarian cancer	<i>Singh</i>	0:20
9:20	CA125 and serological markers of ovarian cancer- Anything new in last decade?	<i>Fagotti</i>	0:20
9:40	Discussion (3 speakers)		0:15
9:55	<i>Coffee break</i>		0:10
10:05	Angiogenic pathways- significance in ovarian cancer and role of targeted anti-angiogenic therapy	<i>Ledermann</i>	0:20
10:25	Homologous Recombination Repair - How should HRD be determined and is it clinically useful? (incl. ovarian and endometrial cancers)	<i>Matias-Guiu</i>	0:20
10:45	Targeting HR Deficiency- when and with which agents?	<i>Ledermann</i>	0:20
11:05	Discussion (3 speakers)		0:15
	<b>Session 2: Rare Gynaecological Tumours</b>	Chair: Fagotti	
11:20	Molecular and genetic pathways and characteristics of low-grade cancers (serous and others)	<i>McCluggage</i>	0:20
11:40	Molecular and Genetic identifiers of Clear Cell Tumours as potential therapeutic targets	<i>Matias-Guiu</i>	0:20
12:00	Pathology and Molecular characteristics of Germ Cell tumours	<i>Kaur</i>	0:20
12:20	Discussion (3 speakers)		0:15
12:35	Wrap up Day 1	<i>Fagotti</i>	

<b>Day 2 – July 2, 2021</b>			
	<b>Session 3: Endometrial Cancers</b>	Chair: Matias-Guiu	
8:30	New molecular classification of Endometrial cancers: routine pathology diagnostics in endometrioid and non-endometrioid cancers?	<i>Bosse</i>	0:20
8:50	Lynch Syndrome, DNA repair genes, microsatellite instability and hormonal drivers in the development of Endometrial cancer	<i>Singh</i>	0:20
9:10	Using the molecular classification of Endometrial Cancers to select adjuvant therapies	<i>Creutzberg</i>	0:20
9:30	Immuno-targeted therapy of Endometrial Cancer	<i>Kroep</i>	0:20
9:50	Discussion (4 speakers)		0:20
10:10	<i>Coffee break</i>		0:10
10:20	Molecular and genetic characteristics of Trophoblastic tumours	<i>Kaur</i>	0:20
10:40	Discussion		0:10
	<b>Session 4: Cervical and Vulvar Cancer</b>	Chair: Creutzberg	
10:50	HPV- role as a driver for carcinogenesis and a biomarker for diagnosis of cervical cancer; molecular pathology of cervical and vulvar cancer	<i>Bosse</i>	0:20
11:10	Vaccination strategies and role in the prevention and treatment of (cervical and) vulvar cancer	<i>van Poelgeest</i>	0:20
11:30	Immunotherapy and Immuno-targeting HPV as a therapeutic strategy	<i>Fagotti</i>	0:20
11:50	Discussion (3 speakers)		0:15
	<b>Session 5: Molecular Tumour Boards</b>	Faculty: Fagotti, Creutzberg, Ledermann and Matias-Guiu	
12:05	How to establish Molecular Tumour Boards in Clinical Practice (interactive)	<i>Bosse &amp; Creutzberg</i>	0:15
12:20	Case study 1 (interactive)	<i>Pletnev</i>	0:25
12:45	Case study 2 (interactive)	<i>van Poelgeest</i>	0:25
13:10	Wrap up Day 2, evaluation	<i>Ledermann</i>	